The Global Toxoplasmosis Testing Market is estimated to reach a high CAGR of 6.4% during the forecast period (2022-2029)
Toxoplasmosis is caused by infection with the protozoan Toxoplasma gondii, an obligate intracellular parasite. The infection produces a wide variety of medical syndromes in humans, land and marine mammals, and various species of poultry. T gondii has been recovered from some places in the sector, with the exception of Antarctica.
The seroprevalence of anti-T gondii antibodies in the human population varies geographically, with prevalence rates approaching 90% in a few European countries, while seropositivity rates in the United States are expected to be between 10% and 15%.
Human immunodeficiency virus (HIV) infection no longer seems to affect T gondii seropositivity, and there no longer seems to be any difference in the rate of toxoplasmosis infection in AIDS patients with and without a cat . Diagnosis of toxoplasmosis is mainly made using Toxoplasmosis Serology Profile (TSP) tests which consist of dye control, indirect immunofluorescent test (IFAT), modified agglutination test (MAT), enzyme immunoassay (ELISA), immunoglobulin controls (IgG, IgM and IgE antibody assessments) and single nucleic acid sequence amplification (iE, PCR), among others. In the toddler, prognosis can be done through tactics that include amniocentesis and ultrasound. Diagnosis can also be made by direct observation of the parasite in stained tissue sections, cerebrospinal fluids (CSF), and blood, but these approaches are less commonly used due to difficulties in obtaining specimens.
Download Free Sample @ https://bit.ly/3sDZcVZ
The increasing incidence of toxoplasmosis, along with the main consumption of meat, red meat and mutton, has led to an increasing demand for powerful testing strategies for T. Gondii through diagnostic laboratories.
Today’s facts indicate that Americans consume 66.18 kilograms of beef annually per capita. US Census data and the Simmons National Consumer Survey (NHCS) observed that 268 million Americans ate bacon in 2020, with more than sixteen million ingesting 5 or more pounds of bacon throughout the season. ‘year. The incidence in other meat-producing animals, as well as sheep, goats and horses, has not changed over the years, as the source of infection in these pasture-stored herbivorous animals has remained unchanged. In farmed sheep, seroprevalence in Europe is logically correlated with age, ranging from lambs (17 to 22%) to adults (65 to 89%).
The prevalence in chickens also varies greatly depending on manufacturing structures. Toxoplasma contamination in industrialized poultry farms is almost absent, while seroprevalence in backyard or free-range chickens is usually excessive, up to 100%. Due to their reliance on near-ground feeding, free-range chickens have certainly been considered an impressive indicator of environmental contamination with Toxoplasma oocysts.
It is generally assumed that around 25-30% of the human population in the area is infected with Toxoplasma. Occurrence varies widely between international sites (10–80%) and often within a single United States or between single groups in the same location.
Low seroprevalences (10 to 30%) have been found in North America, Southeast Asia, Northern Europe and the Sahelian countries of Africa. Moderate prevalence (30–50%) has been observed in central and southern European countries, and high prevalence has been observed in South America and international regions of tropical Africa.
As in animals, many things can affect seroprevalence in humans. Climatic factors affect the survival of oocysts in the environment, and for this reason contamination costs in meat-producing animals play a major role. The highest prevalence is classically localized for international tropical regions with a humid and hot climate, and conversely, the lowest incidence is found for arid countries or less hot countries, however anthropic factors explain a large part of the variations in human seroprevalence, as well as dietary habits. .
By type of test
l Serological test
l Others (PCR, others)
By sample type
l Blood sample
l Amniotic fluid
l Cerebrospinal fluid
Per end user
l Diagnostic laboratories
the Middle East and Africa
See the full report @ https://bit.ly/36V2rjv
The toxoplasmosis testing market is competitive and consists of several major market players. Some of the major players contributing to the market growth are ACON Biotech, Biokit, Biomerieux, Abbott Laboratories, Bio-Rad, Diasorin SpA, Bionote, Atlas Medical, LifeSpan BioSciences, Elitechgroup, Genemedi Suzhou Biotechnology, Gold Standard Diagnostics, Thermo Fisher Scientific ., among others.
Several serological tests are available for the detection of IgG with different sensitivities and specificities offered by companies, such as the Architect® Toxo IgG test (by Abbott Laboratories) which shows specificities and sensitivities ranging from 99.1% to 99.8%. and 92.1% to 99.7%, respectively. Other commonly used automated or semi-automated immunoassays such as Advia Centaur®, AxSym®, Elecsys®, Enzygnost®, Liaison®, Platelia®, Vidas® and Vidia® have various specificities ranging from 99.3% to 100% , while sensitivities range from 93.8% to 100%.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the global toxoplasmosis testing market. For example, in October 2017, Bio-Rad Laboratories received FDA clearance for its BioPlex 2200 ToRC IgM test, a fully automated test for the detection of IgM class antibodies against Toxoplasma gondii, rubella and cytomegalovirus proposed in a multiplexed panel. When used with the BioPlex 2200 System, the BioPlex 2200 ToRC assays, both IgG and IgM, provide a rapid and comprehensive prenatal testing solution for three of the most clinically important diseases. Toxoplasma gondii, rubella and CMV are pathogens commonly associated with congenital diseases and are therefore tested during the first trimester of pregnancy.
Company Name: DataM Intelligence
E-mail: Send an email
Call: +1 877 441 4866
The country: United States